BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11976731)

  • 1. Targeted chemotherapy: chronic myelogenous leukemia as a model.
    Sharifi N; Steinman RA
    J Mol Med (Berl); 2002 Apr; 80(4):219-32. PubMed ID: 11976731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
    Deininger MW; Druker BJ
    Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Signal transduction inhibitor--STI571--a new treatment for chronic myeloid leukemia (CML), which opens a new targeted approach to cancer therapy].
    Nadav L; Eldor A
    Harefuah; 2002 Feb; 141(2):158-62, 222. PubMed ID: 11905088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CML: a model for targeted therapy.
    Cilloni D; Saglio G
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):285-94. PubMed ID: 19959080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
    Michor F
    Trends Pharmacol Sci; 2007 May; 28(5):197-9. PubMed ID: 17412430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
    Ren R
    Nat Rev Cancer; 2005 Mar; 5(3):172-83. PubMed ID: 15719031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
    Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
    Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Imatinib therapy for patients with chronic myelogenous leukemia].
    Usui N
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biology of chronic myelogenous leukemia: implications for imatinib therapy.
    Alvarez RH; Kantarjian H; Cortes JE
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S4-14. PubMed ID: 17292736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.
    Ren R
    Oncogene; 2002 Dec; 21(56):8629-42. PubMed ID: 12476309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors.
    Daley GQ
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):11-4. PubMed ID: 12783369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatment approaches for chronic myelogenous leukemia.
    Druker BJ
    Cancer J; 2001; 7 Suppl 1():S14-8. PubMed ID: 11504279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic myeloid leukemia as a model for modern noncytostatic therapy of malignant diseases. From Virchow to STI 571].
    Mayer J
    Vnitr Lek; 2002 Jan; 48(1):45-9. PubMed ID: 11852587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.